Qomel Co.’s board of directors approved, on October 12, an investment of $1.38 million in US-based biotechnology company Kure Cells, a leading firm specializing in cell therapies, regenerative medicine, and advanced therapeutic technologies.
The share price is set at $94 per share, with Qomel acquiring an estimated post-closing ownership of approximately 1.3%, representing a non-controlling stake. The investment will be fully financed from Qomel’s internal resources.
According to the company, this strategic investment supports Qomel’s long-term goal of advancing the development of high-demand therapeutic products and cutting-edge medical technologies, aligning with its focus on promising sectors in biotech and healthcare.
Qomel does not anticipate any immediate material financial impact from this investment. Any potential future impact will depend on the performance of Kure Cells and the progression of Qomel’s stake. The company affirmed that no related parties are involved in the transaction.
Kure Cells, incorporated under Delaware law following a re-incorporation, is focused on the development of CAR-T cell therapy technologies and research-stage oncology programs, with emphasis on rapid-manufacturing platforms for advanced biological therapies, positioning the company at the forefront of regenerative medicine and innovative therapeutic solutions.
